The present invention relates to novel microporous zirconium silicate compositions having a desired particle size distribution and methods of making those compositions. These compositions have an ideal particle size distribution for use ex vivo, for example in a dialysis exchange cartridge, yet retain many of the desirable properties of prior improved absorbers including high cation exchange capacity. Further, the new zirconium silicate molecular sieve absorbers can be manufactured using a technique that achieves the desired particle size distribution while eliminating the screening step that was previously necessary.

The present invention relates to novel microporous zirconium silicate compositions having a desired particle size distribution and methods of making those compositions. These compositions have an ideal particle size distribution for use ex vivo, for example in a dialysis exchange cartridge, yet retain many of the desirable properties of prior improved absorbers including high cation exchange capacity. Further, the new zirconium silicate molecular sieve absorbers can be manufactured using a technique that achieves the desired particle size distribution while eliminating the screening step that was previously necessary.

The present invention pertains to a method for producing zeolite or zeolite-like crystals using a composition comprising one or more fluorine-containing compounds as a mineralizing agent. Crystals produced by such a method are smaller in size than crystals available in the art and contain few defects. The invention also relates to zeolite and/or zeolite-like crystals obtainable by a method as provided herein as well as crystals defined by any of the structural characteristics provided herein, and the usage thereof such as in the manufacture of thin films and membranes, absorbents, catalysts etc.

The present invention pertains to a method for producing zeolite or zeolite-like crystals using a composition comprising one or more fluorine-containing compounds as a mineralizing agent. Crystals produced by such a method are smaller in size than crystals available in the art and contain few defects. The invention also relates to zeolite and/or zeolite-like crystals obtainable by a method as provided herein as well as crystals defined by any of the structural characteristics provided herein, and the usage thereof such as in the manufacture of thin films and membranes, absorbents, catalysts etc.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention concerns the use, for gas separation and/or gas drying, of at least one zeolite adsorbent material comprising at least one type A zeolite, said adsorbent having an external surface area greater than 20 m.sup.2.g.sup.1, a non-zeolite phase (PNZ) content such that O<PNZ30%, and an Si/Al atomic ratio of between 1.0 and 2.0. The invention also concerns a zeolite adsorbent material having an Si/Al ratio of between 1.0 and 2.0, a mesoporous volume of between 0.07 cm.sup.3.Math.g.sup.1 and 0.18 cm.sup.3.Math.g.sup.1, a (Vmicro-Vmeso)/Vmicro ratio of between 3 and 1.0, non-inclusive, and a non-zeolite phase (PNZ) content such that 0<PNZ30%.

The present invention concerns the use, for gas separation and/or gas drying, of at least one zeolite adsorbent material comprising at least one type A zeolite, said adsorbent having an external surface area greater than 20 m.sup.2.g.sup.1, a non-zeolite phase (PNZ) content such that O<PNZ30%, and an Si/Al atomic ratio of between 1.0 and 2.0. The invention also concerns a zeolite adsorbent material having an Si/Al ratio of between 1.0 and 2.0, a mesoporous volume of between 0.07 cm.sup.3.Math.g.sup.1 and 0.18 cm.sup.3.Math.g.sup.1, a (Vmicro-Vmeso)/Vmicro ratio of between 3 and 1.0, non-inclusive, and a non-zeolite phase (PNZ) content such that 0<PNZ30%.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.